MAD2 in the Spotlight as a Cancer Therapy Regulator

MAD2 is a key protein required for mitotic checkpoint function and for the maintenance of accuracy on the mitotic process of every cell cycle. Deregulation of MAD2 is associated with both progression and poor prognosis in cancer disease. However, new evidence highlights the implication of MAD2 in other biological functions besides its classical Mitotic checkpoint implication, such as apoptosis, senescence and also DNA damage repair, which can ultimately define the response to a specific treatment. Development of novel therapeutic approaches and optimization of the existing therapies are now required for the design of successful treatments of cancer. MAD2 is emerging as a new key target for the design of more effective and personalized treatments in cancer disease.